OBJECTIVES: When single-dose oritavancin was introduced in 2014 for the treatment of acute bacterial skin and skin structure infection, it was hypothesized that its single-dose formulation may help US hospitals reduce use of inpatient beds through treatment entirely in the outpatient setting and reduction in length of stay (LOS) for admitted patients. This analysis sought to assess the real world impact of oritavancin to US hospitals. METHODS: Data were extracted from the Premier Hospital Database for the first full year of oritavancin availability (2015). Hospital admission rates and LOS were assessed for patients receiving oritavancin for skin infection and compared with patients receiving any other intravenous (IV) antibiotic grouped by infection severity (no systemic symptoms, with systemic symptoms, life-threatening infection) and presence of comorbid conditions using Charlson Comorbidity Index score (CCI). RESULTS: There were 208,113 records for patients 18+ with a primary diagnosis of skin infection and administration of IV antibiotic. Among 203 patients who received oritavancin, the average CCI was 1.46; 24.1% patients CCI≥3; 9.8% life-threatening condition (4.4%) or systemic symptoms (5.4%). 144 (70.9%) oritavancin patients were treated as outpatients. For the 59 patients who were hospitalized (LOS=4.0d), 56 patients received oritavancin after the discharge of hospitalization or on day of discharge. Compared to patients receiving other IV antibiotics, the patients who received oritavancin had consistently lower admission rates (rate reduction up to 45.4%) across all levels of infection severity and CCI. If admitted, oritavancin patients had shorter LOS (LOS reduction up to 1.8 days) across all severity levels except CCI=1 group. CONCLUSIONS: This analysis finds that use of oritavancin avoided hospitalization and shortened length of stay for skin infection patients. As skin infections represent 2% of all US hospital admissions, increased use of oritavancin may represent an opportunity to recover several hundred thousand bed days for use with other patients.